JP2021526138A5 - - Google Patents

Info

Publication number
JP2021526138A5
JP2021526138A5 JP2020565354A JP2020565354A JP2021526138A5 JP 2021526138 A5 JP2021526138 A5 JP 2021526138A5 JP 2020565354 A JP2020565354 A JP 2020565354A JP 2020565354 A JP2020565354 A JP 2020565354A JP 2021526138 A5 JP2021526138 A5 JP 2021526138A5
Authority
JP
Japan
Prior art keywords
composition according
composition
mtor inhibitor
individual
nanoparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526138A (ja
JP7561628B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033372 external-priority patent/WO2019226685A1/en
Publication of JP2021526138A publication Critical patent/JP2021526138A/ja
Publication of JP2021526138A5 publication Critical patent/JP2021526138A5/ja
Application granted granted Critical
Publication of JP7561628B2 publication Critical patent/JP7561628B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565354A 2018-05-22 2019-05-21 肺高血圧症を処置するための方法および組成物 Active JP7561628B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862675110P 2018-05-22 2018-05-22
US62/675,110 2018-05-22
US201962810290P 2019-02-25 2019-02-25
US62/810,290 2019-02-25
US201962820842P 2019-03-19 2019-03-19
US201962820838P 2019-03-19 2019-03-19
US62/820,838 2019-03-19
US62/820,842 2019-03-19
PCT/US2019/033372 WO2019226685A1 (en) 2018-05-22 2019-05-21 Methods and compositions for treating pulmonary hypertension

Publications (3)

Publication Number Publication Date
JP2021526138A JP2021526138A (ja) 2021-09-30
JP2021526138A5 true JP2021526138A5 (cg-RX-API-DMAC7.html) 2022-05-27
JP7561628B2 JP7561628B2 (ja) 2024-10-04

Family

ID=68615837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565354A Active JP7561628B2 (ja) 2018-05-22 2019-05-21 肺高血圧症を処置するための方法および組成物

Country Status (14)

Country Link
US (1) US20210085621A1 (cg-RX-API-DMAC7.html)
EP (1) EP3810091B1 (cg-RX-API-DMAC7.html)
JP (1) JP7561628B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210024471A (cg-RX-API-DMAC7.html)
CN (1) CN112423737A (cg-RX-API-DMAC7.html)
AU (1) AU2019274516B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020023431A2 (cg-RX-API-DMAC7.html)
CA (1) CA3100905A1 (cg-RX-API-DMAC7.html)
IL (1) IL278814A (cg-RX-API-DMAC7.html)
MX (2) MX2020012478A (cg-RX-API-DMAC7.html)
NZ (1) NZ770290A (cg-RX-API-DMAC7.html)
SG (1) SG11202011462SA (cg-RX-API-DMAC7.html)
TW (1) TW202015659A (cg-RX-API-DMAC7.html)
WO (1) WO2019226685A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
SMT202100642T1 (it) 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
MX2021011230A (es) * 2019-03-19 2022-03-11 Abraxis Bioscience Llc Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
IL292439B2 (en) 2019-10-28 2026-05-01 Abraxis Bioscience Llc Pharmaceutical preparations of albumin and rapamycin
KR20220120823A (ko) 2021-02-24 2022-08-31 주식회사 만도 랙구동형 동력 보조 조향장치
CN114732789B (zh) * 2022-05-05 2023-08-22 中国药科大学 一种用于治疗肺动脉高压的复方长效递药系统及其制备

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
EP3345631A1 (en) 2005-02-18 2018-07-11 Abraxis BioScience, LLC Drugs with improved hydrophobicity for incorporation in medical devices
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
EP3417859A1 (en) 2007-03-07 2018-12-26 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
CA2963085C (en) * 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
CA2990705A1 (en) * 2015-06-29 2017-01-05 Abraxis Bioscience, Llc Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy
SMT202100642T1 (it) * 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
US20180177771A1 (en) * 2015-06-29 2018-06-28 Abraxis Bioscience, Llc Biomarkers for nanoparticle compositions
JP2018521058A (ja) * 2015-06-29 2018-08-02 アブラクシス バイオサイエンス, エルエルシー ナノ粒子mTOR阻害剤併用治療を使用して固形腫瘍を処置する方法
KR102475256B1 (ko) * 2016-09-28 2022-12-08 아브락시스 바이오사이언스, 엘엘씨 미토콘드리아 및 대사 장애를 치료하는 방법

Similar Documents

Publication Publication Date Title
JP4938905B2 (ja) 選択的s1p1レセプターアゴニストの投与法
JP2023088944A5 (cg-RX-API-DMAC7.html)
Vorhies et al. Drug treatment of pulmonary hypertension in children
US20100267735A1 (en) Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
CN102006875A (zh) 吡铂和贝伐单抗治疗结直肠癌的用途
CN1516588A (zh) 用于局部眼科应用的溴莫尼定和噻吗洛尔的组合
CN1856339A (zh) 肺动脉高血压症治疗的伊洛前列素联合疗法
JP2002529405A (ja) 心臓血管系疾患による発病率及び死亡率減少のためのアンギオテンシン変換酵素阻害薬及びアルドステロン拮抗薬の併用療法
JP2020502261A5 (cg-RX-API-DMAC7.html)
JP2022502492A5 (cg-RX-API-DMAC7.html)
CN115803028A (zh) 用于治疗慢性肾病的齐泊腾坦和达格列净的组合
JP2017128610A (ja) 併用als療法
JP2025526021A (ja) 肺動脈性高血圧症(pah)を治療するためのチロシンキナーゼ阻害剤とアクチビン2型受容体アンタゴニストの併用療法
US20070142266A1 (en) Combination comprising a P-gp inhibitor and an anti-epileptic drug
US20240016814A1 (en) Method of treating hypertension
US20050080018A1 (en) Use of alkanoyl l-carnitine for the treatment of erectile dysfunction
US10576083B2 (en) Method of treating pulmonary arterial hypertension
WO2015069839A1 (en) Combination therapy for treating pulmonary hypertension
US20030087911A1 (en) Methods and compositions for treating hypertension
CN108472333A (zh) 组合
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
RU2020142051A (ru) Способы и композиции для лечения легочной гипертензии
TW201806599A (zh) 用於快速開始抗抑鬱作用之給藥方案
JP6420923B1 (ja) 医薬
CN1976708A (zh) 包含bcrp抑制剂和4-(4-甲基哌嗪-1-基甲基)-n-[4-甲基-3-(4-吡啶-3-基)嘧啶-2-基氨基)苯基]-苯甲酰胺的组合